抗血小板口服 Ticlopidine is an antiplatelet drug with a mechanism of action different from that of aspirin or other nonsteroidal antiinflammatory drugs. Ticlopidine decreases platelet aggregation, and prolongs bleeding time. It may be useful in the prevention of thromboembolic disorders, cardiovascular mortality, stroke, myocardial infarction, and vaso-occlusive sickle cell crisis.

Ticlopidine, a thienopyridine derivative P2Y12 platelet adenosine diphosphate (ADP)-receptor antagonist, is a platelet-aggregation inhibitor.

Hypersensitivity, active bleeding disorders, neutropenia or thrombocytopenia; severe liver impairment. Ticlopidine should be discontinued if the absolute neutrophil count falls below 1200/mm3 or if the platelet count falls below 80,000/mm3.

B

It is not known whether ticlopidine is distributed into human milk. Because of the potential for serious adverse reactions to ticlopidine in nursing infants, a decision should be made whether to discontinue nursing or the drug, taking into account the importance of the drug to the woman.

Neutropenia, thrombocytopenia, leukopenia, agranulocytosis, pancytopenia, thrombocytopenic purpura, hemorrhage, ecchymosis, epostaxis, menorrhagia, gastro-intestinal bleeding, dizziness, nausea, vomiting, abdominal cramps, dyspepsia, flatulence, anorexia, liver damage, rash, urticaria.

PO 250mg BID, maintain patency in patients on hemodialysis: 200mg QD, duration ranged from 9 days (post-operative thrombosis) to 6 months.

In patients with renal impairment, reduction of ticlopidine hydrochloride dosage or discontinuance of the drug may be necessary if hemorrhagic or hematopoietic complications occur.